Tumor Antigen-Based Anticancer Vaccine and Immunotherapy
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 28 February 2025 | Viewed by 57
Special Issue Editor
Interests: oncology; virology; molecular biology; cancer research; cancer vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Anti-cancer vaccines and immunotherapies are the most recent and successful strategies against cancer. Since the early 2000s, focused target therapy has replaced non-selective cytotoxic chemotherapy, leading to significant advancements in cancer treatment. Small interfering molecules and monoclonal antibodies have effectively modulated immune responses but have limited contribution to the active immune response, which is the goal of immunotherapy. This Special Issue focuses on research activities addressing the transformation of immunologically inert tumors into immunologically reactive cancers suitable for specific control or elimination from the host immune system. We welcome manuscripts addressing critical in vitro and in vivo issues to optimize strategies, from identifying tumor-specific antigens and tumor-associated antigen epitopes to exploring immune checkpoint inhibitors.
In this Special Issue, original research articles and reviews are welcome.
Research areas may include the following:
- Identification of tumor-specific antigen (TSA)/tumor-associated antigens (TAA);
- Adjuvants;
- Characterization and selection of inhibitory checkpoints;
- Antigens and CPIs and their temporal administration;
- Regulatory compliance for the development of such molecules and clinical studies.
We look forward to receiving your contributions.
Dr. Franco M. Buonaguro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune check point inhibitors (CPIs)
- PD-1/PD-L1 inhibitors
- CTLA-4 inhibitors
- LAG-3 inhibitors
- anti-HPV adjuvant and therapeutic vaccines
- TSAs
- TAAs
- cancer vaccines
- adjuvants for cancer vaccines
- cancer vaccines as neo-adjuvants
